The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?
dc.contributor.author | Giovannonin, G | en_US |
dc.contributor.author | Baker, D | en_US |
dc.contributor.author | Schmierer, K | en_US |
dc.date.accessioned | 2016-04-21T15:49:50Z | |
dc.date.available | 2014-11-12 | en_US |
dc.date.issued | 2015-01 | en_US |
dc.identifier.issn | 2211-0348 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/11979 | |
dc.format.extent | 3 - 5 | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | MULTIPLE SCLEROSIS AND RELATED DISORDERS | en_US |
dc.subject | Multiple sclerosis | en_US |
dc.subject | Drug development | en_US |
dc.subject | Pharmaceutical industry | en_US |
dc.subject | Simvastatin | en_US |
dc.subject | Caldribine | en_US |
dc.title | The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis? | en_US |
dc.type | Article | |
dc.rights.holder | © 2014 Elsevier B.V. | |
dc.identifier.doi | 10.1016/j.msard.2014.11.005 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000349666400002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 1 | en_US |
pubs.notes | No embargo | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 4 | en_US |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |